Sean Harper

Type: Person
Name: Sean Harper
First reported 18 hours ago - Updated 18 hours ago - 1 reports

Amgen reports positive data from kidney disease drug trial

:06 in Pharmaceutical Company Product News Amgen has announced positive data from a phase III study evaluating its drug AMG 416 in the treatment of conditions relating to chronic kidney disease. The drug was able to meet all of its primary and secondary ... [Published Zenopa - 18 hours ago]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Amgen Posts AMG 416 Phase 3 Results

Amgen reported that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease, receiving hemodialysis, met its primary and all secondary endpoints. "Secondary ... [Published Individual.com - Jul 22 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Amgen: Grappling With The Reality Of Patent Expiries

Summary Amgen has been recently awarded the breakthrough status for its new drug to treat adults with acute lymphoblastic leukemia. The prevalence rate is quite high, with limited treatment options available. If authorized, Amgen can exploit the first-mover ... [Published Seeking Alpha - Jul 18 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 2 reports

Amgen announces positive Phase III results for AMG 416 in kidney disease

USA-based Amgen (Nasdaq: AMGN), the world's leading independent biotech firm, has said its Phase III study evaluating AMG 416 (formerly known as velcalcetide) in the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease, ... [Published Pharma Letter - Jul 18 2014]
First reported Jul 06 2014 - Updated Jul 06 2014 - 1 reports

Newtown man charged with stealing credit cards, drivers licenses

By Pattie PriceCORRESPONDENTSean Conner, 33, of Newtown waived a hearing on the charges of receiving stolen property. In exchange for the waiver, the charge of possession of drug paraphernalia was withdrawn. The charges stem from an incident 11:02 a.m., ... [Published News of Delaware County - Jul 06 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Fast Track Status for Amgen Leukemia Drug

The U.S. Food and Drug Administration has given Breakthrough Therapy Designation status to blinatumomab, a drug in development at Amgen Inc. for treating certain cancers.The Thousand Oaks pharmaceutical company said the designation resulted from a recent ... [Published Los Angeles Business Journal - Jul 03 2014]
First reported Jul 01 2014 - Updated Jul 02 2014 - 4 reports

FDA breakthrough for Amgen

Amgen has taken a major step down the road to getting its investigational cancer drug blinatumomab onto the market after the US regulator granted it breakthrough therapy designation.The bispecific T cell engager (BiTE) antibody is being looked at in adults ... [Published Pharmafocus - Jul 02 2014]
First reported Jun 25 2014 - Updated Jun 25 2014 - 1 reports

Amgen joins alliance to study personalised lung cancer therapies

:45 in Pharmaceutical Company Product News Amgen has announced that it will be allying with the US National Cancer Institute and a number of other public and private sector partners on new lung cancer research. The firm will join fellow pharmaceutical ... [Published Zenopa - Jun 25 2014]
First reported Jun 18 2014 - Updated Jun 18 2014 - 1 reports

Genome-driven lung cancer trial launches

Genentech and Roche’s PI3 kinase inhibitor GDC0032 features in the trialAmgen, Genentech, Pfizer, AstraZeneca and MedImmune - AstraZeneca’s global biologics R&D arm - have each put investigative treatments into a new trial for patients with advanced squamous ... [Published Pharmafocus - Jun 18 2014]
Entities: Lung Cancer, Genome, Cancer
First reported Jun 16 2014 - Updated Jun 16 2014 - 1 reports

Amgen Lung-Cancer Drug Goes to Trial

Amgen Inc. announced on Monday it is joining a high-level research partnership that will test its experimental cancer drug rilotumumab on lung-cancer patients.The Thousand Oaks biotech said it will collaborate with the National Cancer Institute and other ... [Published Los Angeles Business Journal - Jun 16 2014]
First reported May 22 2014 - Updated May 23 2014 - 1 reports

Blackshades RAT leads to 97 Arrests in 16 countries

On May 19, 2014, the FBI announced a worldwide coordinated action against criminals who created, sold, and used a Remote Administration Trojan (RAT) known as BlackShades. In the FBI's BlackShades Press Release they shared that 40 participating FBI ... [Published Security Bloggers Network - May 22 2014]
First reported Mar 17 2014 - Updated Mar 17 2014 - 1 reports

Amgen reports positive results of Phase III melanoma trial

Amgen has reported positive results from its Phase III trial evaluating talimogene laherparepvec in patients with injectable unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).Findings from ... [Published Pharmaceutical Business Review - Mar 17 2014]

More Content

All (21) | News (18) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Amgen reports positive data from kidney disease... [Published Zenopa - 18 hours ago]
Amgen Posts AMG 416 Phase 3 Results [Published Individual.com - Jul 22 2014]
Amgen announces positive Phase III results for ... [Published Pharma Letter - Jul 18 2014]
Amgen's Sensipar follow-up clears phase III trial [Published PMLive - Jul 18 2014]
Amgen: Grappling With The Reality Of Patent Exp... [Published Seeking Alpha - Jul 18 2014]
Amgen's kidney dialysis drug clears its first P... [Published FierceBiotech - Jul 18 2014]
Newtown man charged with stealing credit cards,... [Published News of Delaware County - Jul 06 2014]
Fast Track Status for Amgen Leukemia Drug [Published Los Angeles Business Journal - Jul 03 2014]
FDA breakthrough for Amgen [Published Pharmafocus - Jul 02 2014]
US 'breakthrough' status for Amgen's leukaemia ... [Published Pharma Times - Jul 02 2014]
Breakthrough status for Amgen’s blinatumomab in... [Published Pharma Letter - Jul 01 2014]
Angling for early OK, Amgen wins 'breakthrough'... [Published FierceBiotech - Jul 01 2014]
Amgen joins alliance to study personalised lung... [Published Zenopa - Jun 25 2014]
Genome-driven lung cancer trial launches [Published Pharmafocus - Jun 18 2014]
Amgen Lung-Cancer Drug Goes to Trial [Published Los Angeles Business Journal - Jun 16 2014]
Blackshades RAT leads to 97 Arrests in 16 count... [Published Security Bloggers Network - May 22 2014]
Amgen reports positive results of Phase III mel... [Published Pharmaceutical Business Review - Mar 17 2014]
Amgen’s Cholesterol-Fighting Drug Succeeds Yet ... [Published Wall St. Cheat Sheet - Jan 31 2014]
MGH-Broad-Amgen collaboration to develop new in... [Published Pharmaceutical Technology - Jan 17 2014]
Amgen releases interim results of Phase III tri... [Published Pharmaceutical Business Review - Nov 20 2013]
Forbes Health Summit: Industry Leaders Ponder t... [Published Pharmaceutical Executive - Oct 15 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Blackshades RAT leads to 97 Arrests in 16 count... [Published Security Bloggers Network - May 22 2014]
On May 19, 2014, the FBI announced a worldwide coordinated action against criminals who created, sold, and used a Remote Administration Trojan (RAT) known as BlackShades. In the FBI's BlackShades Press Release they shared that 40 participating FBI ...
Amgen’s Cholesterol-Fighting Drug Succeeds Yet ... [Published Wall St. Cheat Sheet - Jan 31 2014]
Amgen Inc.’s ( NASDAQ:AMGN ) experimental anti-cholesterol drug, evolocumab, was successful in its fifth late-stage trial. The treatment targets a protein called PCSK9 that’s typically associated with high levels of “bad” cholesterol (or, LDL),  ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.